文献速递白血病

MICA/B抗体诱导巨噬细胞介导的抗急性髓系白血病免疫

MICA/B antibody induces macrophage-mediated immunity against acute myeloid leukemia.
PubMed 文献 · Blood · 2022-01-01

该研究在免疫健全小鼠的2个AML模型中证实,MICA/B抗体7C6可显著抑制白血病生长,其疗效依赖巨噬细胞,机制为抗体依赖性吞噬作用。组蛋白去乙酰化酶抑制剂罗米地辛可上调AML细胞MICB mRNA,与7C6联用增加表面MICA/B表达并促进人巨噬细胞吞噬AML细胞,在人源化模型中降低白血病负荷。

要点

  • 7C6通过Fc受体信号触发巨噬细胞对AML细胞的抗体依赖性吞噬。
  • 罗米地辛上调MICB mRNA,与7C6联用稳定蛋白并增加表面MICA/B表达。
  • 联合治疗在人源化AML模型中降低白血病负荷,支持临床转化。

核心结论

  • 抑制MICA/B脱落可通过Fc受体信号促进巨噬细胞驱动的抗AML免疫,并与表观遗传调节剂协同。

研究设计与样本

  • 在免疫健全小鼠的2个AML模型中评估7C6的疗效,并开展机制研究。
  • 使用人AML细胞系、多能干细胞来源的AML原始细胞和白血病干细胞,以及3例未治疗AML患者原代细胞进行体外验证。
  • 在人源化AML模型中评估7C6联合罗米地辛的疗效。

主要发现

  • 7C6在免疫健全小鼠的2个AML模型中强效抑制白血病生长。
  • 巨噬细胞对7C6的疗效必不可少,7C6触发对AML细胞的抗体依赖性吞噬。
  • 罗米地辛增加AML细胞MICB mRNA,7C6稳定翻译后的蛋白。
  • 联合用药显著增加人AML细胞系、干细胞来源AML原始细胞和白血病干细胞及3例患者原代细胞的表面MICA/B表达。
  • 7C6联合罗米地辛促进人巨噬细胞吞噬AML细胞,并在人源化模型中降低白血病负荷。

临床怎么用

  • MICA/B抗体联合组蛋白去乙酰化酶抑制剂可能成为AML的免疫治疗新策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) is a clonal hematopoietic stem and progenitor cell malignancy characterized by poor clinical outcomes. Major histocompatibility complex class I polypeptide-related sequence A and B (MICA/B) are stress proteins expressed by cancer cells, and antibody-mediated inhibition of MICA/B shedding represents a novel approach to stimulate immunity against cancers. We found that the MICA/B antibody 7C6 potently inhibits the outgrowth of AML in 2 models in immunocompetent mice. Macrophages were essential for therapeutic efficacy, and 7C6 triggered antibody-dependent phagocytosis of AML cells. Furthermore, we found that romidepsin, a selective histone deacetylase inhibitor, increased MICB messenger RNA in AML cells and enabled subsequent stabilization of the translated protein by 7C6. This drug combination substantially increased surface MICA/B expression in a human AML line, pluripotent stem cell-derived AML blasts and leukemia stem cells, as well as primary cells from 3 untreated patients with AML. Human macrophages phagocytosed AML cells following treatment with 7C6 and romidepsin, and the combination therapy lowered leukemia burden in a humanized model of AML. Therefore, inhibition of MICA/B shedding promotes macrophage-driven immunity against AML via Fc receptor signaling and synergizes with an epigenetic regulator. These results provide the rationale for the clinical testing of this innovative immunotherapeutic approach for the treatment of AML.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Alves da Silva PH, Xing S, Kotini AG, et al. MICA/B antibody induces macrophage-mediated immunity against acute myeloid leukemia. Blood. 2022. PMID: 34359073. doi:10.1182/blood.2021011619

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。